Description
Vildagliptin sold as Glucowell in Kenya is an oral anti-hyperglycemic agent of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It’s the generic version of the original GALVUS. Vildagliptin inhibits the inactivation of GLP-1[2][3] and GIP[3] by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.[2]
Reviews
There are no reviews yet.